Welcome to epgonline.org - the website for healthcare professionals

What's new?

  • ,Whats new CLL KC

    Launch of Chronic Lymphocytic Leukaemia (CLL)
    Knowledge Centre

    The new CLL Knowledge Centre contains useful resources for healthcare professionals
    treating this condition. There are three key areas: ‘Disease awareness’ (epidemiology,
    pathophysiology, diagnosis and treatment), ‘Events’ (upcoming meetings and congresses)
    and ‘Resources’ (links to useful sites and organisations).

  • ,AIKN CDI May Update

    Anti-Infectives Knowledge Network (AIKN) CDI Updates

    The Anti-Infectives Knowledge Network – Clostridium difficile infection (AIKN-CDI) has
    recently been updated with new content including presentation slides from EBMT and
    ECCMID 2015, a gut microflora animation unveiled at the Astellas stand during
    ECCMID 2015, recent articles added to the ‘CDI perspectives’ section and the
    opportunity to participate in a second round consensus questionnaire for the
    ​largest ever clinician consensus report.

    May 2015 MYC/15/0020/EUb

  • ,Whats New CSU

    Launch of Chronic Spontaneous Urticaria (CSU)
    Knowledge Centre

    A new Chronic Spontaneous Urticaria (CSU) Knowledge Centre has
    launched on epgonline.org to raise awareness and improve early diagnosis
    of the condition. Healthcare professionals will have free access to a
    disease overview, recent symposia highlights, a video channel and useful resources.

  • ,Whats new Psoriasis Knowledge centre

    Launch of Psoriasis Knowledge Centre

    A new Psoriasis Knowledge Centre has launched on epgonline.org
    to provide dermatologists, family medicine physicians and other healthcare
    professionals with free access to relevant information on psoriasis including
    pathophysiology, comorbidities, signs and symptoms, diagnosis and more.

  • ,What's New ECCMID IFI

    Anti-Infectives Knowledge Network (AIKN) IFI Updates

    The AIKN-IFI has been updated with four presentations from the Astellas-sponsored
    symposium at the 25th European Congress of Clinical Microbiology and Infectious
    Diseases (ECCMID) 2015
    . The congress took place on 25–28 April in Copenhagen,
    Denmark. Visit the congresses section of this resource to view and download the slides
    free of charge.

    May 2015 MYC/15/0040/EUb

Latest News

Humira (adalimumab) is EU approved to treat hidradenitis suppurativa - Abbvie


AbbVie has announced that Humira (adalimumab) is EU approved for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS treatment. Humira is now the first ...

FDA approves Spritam Zipdose (levetiracetam) for epilepsy-Aprecia Pharmaceuticals


The FDA has approved Spritam (levetiracetam), from Aprecia Pharmaceuticals, for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and ...

S 297995 (naldemedine) meets primary endpoint in a phase III study for opioid-induced constipation- Shionogi


Once-daily S 297995 (naldemedine), from Shionogi, met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. This is the third Phase ...

EU approves Omidria (phenylephrine and ketorolac injection) for use in cataract surgery- Omeros Corp


Omeros Corporation announced that the European Commission has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union for use in cataract surgery and lens replacement procedures to maintain ...

LX 1032 (telotristat etiprate) meets primary endpoint in cancer patients with carcinoid syndrome- Lexicon Pharmaceuticals


Lexicon Pharmaceuticals announced that the pivotal TELESTAR Phase III clinical trial of oral LX 1032 (telotristat etiprate) met its primary endpoint, showing benefit in treating cancer patients with carcinoid syndrome that is not adequately ...

Phase III data on BAX 111 (recombinant von Willebrand Factor) published in Blood- Baxalta


Baxalta Inc announced the publication of pivotal phase III data for BAX 111 (recombinant von Willebrand Factor) in Blood, the journal of the American Society of Hematology. The data showed that 100 percent of the patients treated with BAX 111, a ...

Shire acquires Foresight Biotherapeutics Inc for $300 million and with it FST 100


Shire plc announced that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million. With the acquisition, Shire acquires the global rights to FST-100 (topical ophthalmic drops combining 0.6% povidone iodine ...

Recent Updates


Clinical Guidelines

European Stroke Organisation (ESO) guidelines for the management of temperature in patients with acute ischemic stroke

Anaemia management in people with chronic kidney disease

Lower urinary tract symptoms: The management of lower urinary tract symptoms in men

Suspected cancer: recognition and referral

Medical Journals

Seasonality of hepatitis: a review update.

The Ethics of Breast Surgery

Reliability of dipstick assay in predicting urinary tract infection.

Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients.

epgonline.org Social

Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages



News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors